Shopping Cart 0
Cart Subtotal
USD 0

The Medicines Company (MDCO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

The Medicines Company (TMC) is a biopharmaceutical company, which provides medical solutions for improving health conditions in patients under critical care. The company's product portfolio comprises marketed products a peptide compound that inhibits an intravenous direct thrombin and needle-free patient-controlled system for short term management of acute postoperative pain for adults requiring opioid analgesia in the hospital. Its pipeline products include an investigational anesthetic agent; and an investigational lipid-lowering drug. TMC also provides acute care generic pharmaceuticals products. The company offers its products for major therapeutic areas, which include surgery and perioperative care, acute care, and cardiovascular care. It has offices and other facilities in the US, the UK, Canada and other European countries. TMC is headquartered in Parsippany, New Jersey, the US.

The Medicines Company (MDCO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

The Medicines Company, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

The Medicines Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

The Medicines Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

The Medicines Company, Medical Devices Deals, 2012 to YTD 2018 10

The Medicines Company, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

The Medicines Company, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Medicines Company Exercises Option to Acquire Recothrom from Bristol-Myers Squibb for USD132 Million 13

Venture Financing 14

Annovation BioPharma Raises USD 8 Million In Series A Financing 14

Annovation BioPharma Raises USD 2 Million In Venture Financing 15

Partnerships 16

The Medicines Company Enters into Agreement with BARDA 16

Medicines Company Enters into Distribution Agreement with Sandoz for Angiomax 17

Licensing Agreements 18

Medicines Company Enters into Licensing Agreement with SciClone 18

Medicines Company Enters Into Licensing Agreement With Bristol-Myers Squibb For Recothrom 20

Medicines Company Enters Into Licensing Agreement With Alnylam Pharma To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 22

Medicines Company Enters Into Licensing Agreement With APP For Acute Care Generic Products 24

Equity Offering 25

The Medicines Company Completes Public Offering Of Shares For USD 201.3 Million 25

Debt Offering 26

The Medicines Company Raises USD402.5 Million in Private Placement of 2.75% Notes Due 2023 26

Medicines Company Raises USD400 million in Private Placement of 2.5% Notes Due 2022 28

The Medicines Company Completes Private Placement Of Notes For USD 275 Million 29

Asset Transactions 30

Melinta Therapeutics Acquires Infectious Disease Business Unit from The Medicines Company 30

Chiesi Farmaceutici Acquires Cardiovascular Assets of The Medicines Company for up to USD743.8 Million 32

Mallinckrodt Acquires Three Topical Hemostasis Drugs from Medicines Company 34

Acquisition 36

Medicines Company Acquires Annovation Biopharma 36

Medicines Company Acquires Rempex Pharma For USD 474 Million 37

Medicines Company Completes Acquisition Of ProFibrix For Up To USD 240 Million 39

Medicines Company Completes Acquisition Of Incline Therapeutics For USD 185 Million 41

The Medicines Company-Key Competitors 43

The Medicines Company-Key Employees 44

The Medicines Company-Locations And Subsidiaries 45

Head Office 45

Other Locations & Subsidiaries 45

Recent Developments 47

Financial Announcements 47

Aug 01, 2018: The Medicines Company Reports Second-Quarter 2018 Results 47

Apr 25, 2018: The Medicines Company Reports First-Quarter 2018 Results 49

Feb 21, 2018: The Medicines Company Reports Fourth-Quarter and Full-Year 2017 Business and Financial Results 51

Oct 25, 2017: The Medicines Company Reports Third-Quarter 2017 Business and Financial Results 53

Aug 09, 2017: The Medicines Company Reports Second Quarter 2017 Business and Financial Results 55

Apr 26, 2017: The Medicines Company Reports First-Quarter 2017 Financial Results 57

Feb 28, 2017: The Medicines Company Reports Fourth-Quarter and Full-Year 2016 Financial Results 58

Corporate Communications 60

Mar 27, 2018: The Medicines Company Announces Chief Financial Officer Transition 60

Feb 27, 2018: The Medicines Company Appoints Dr. Sarah Schlesinger to Its Board of Directors 61

Nov 15, 2017: The Medicines Company Names Dr. Fred Eshelman as Executive Chairman; Appoints Geno Germano to Its Board of Directors 62

Mar 31, 2017: The Medicines Company Appoints Paris Panayiotopoulos to Its Board of Directors 63

Clinical Trials 64

Apr 26, 2017: The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA on Phase III Clinical Program for Inclisiran 64

Mar 17, 2017: The Medicines Company and Alnylam Pharmaceuticals Report Positive Final Results from ORION-1 Phase II Study of Inclisiran 66

Mar 14, 2017: The Medicines Company to Webcast Presentation of ORION-1 Phase II Study of Inclisiran at ACC.17 68

Jan 25, 2017: The Medicines Company to Present Results from ORION-1 Phase 2 Study of Inclisiran at the American College of Cardiology's 66th Annual Scientific Session 69

Jan 08, 2017: The Medicines Company Announces Positive Top-Line Results from Day 180 Interim Analysis in Ongoing ORION-1 Phase 2 Study of Inclisiran 70

Appendix 72

Methodology 72

About GlobalData 72

Contact Us 72

Disclaimer 72


List Of Figure

List of Figures

The Medicines Company, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

The Medicines Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

The Medicines Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

The Medicines Company, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

The Medicines Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

The Medicines Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

The Medicines Company, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

The Medicines Company, Pharmaceuticals & Healthcare, Key Facts, 2017 2

The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

The Medicines Company, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

The Medicines Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

The Medicines Company, Deals By Therapy Area, 2012 to YTD 2018 9

The Medicines Company, Medical Devices Deals, 2012 to YTD 2018 10

The Medicines Company, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Medicines Company Exercises Option to Acquire Recothrom from Bristol-Myers Squibb for USD132 Million 13

Annovation BioPharma Raises USD 8 Million In Series A Financing 14

Annovation BioPharma Raises USD 2 Million In Venture Financing 15

The Medicines Company Enters into Agreement with BARDA 16

Medicines Company Enters into Distribution Agreement with Sandoz for Angiomax 17

Medicines Company Enters into Licensing Agreement with SciClone 18

Medicines Company Enters Into Licensing Agreement With Bristol-Myers Squibb For Recothrom 20

Medicines Company Enters Into Licensing Agreement With Alnylam Pharma To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 22

Medicines Company Enters Into Licensing Agreement With APP For Acute Care Generic Products 24

The Medicines Company Completes Public Offering Of Shares For USD 201.3 Million 25

The Medicines Company Raises USD402.5 Million in Private Placement of 2.75% Notes Due 2023 26

Medicines Company Raises USD400 million in Private Placement of 2.5% Notes Due 2022 28

The Medicines Company Completes Private Placement Of Notes For USD 275 Million 29

Melinta Therapeutics Acquires Infectious Disease Business Unit from The Medicines Company 30

Chiesi Farmaceutici Acquires Cardiovascular Assets of The Medicines Company for up to USD743.8 Million 32

Mallinckrodt Acquires Three Topical Hemostasis Drugs from Medicines Company 34

Medicines Company Acquires Annovation Biopharma 36

Medicines Company Acquires Rempex Pharma For USD 474 Million 37

Medicines Company Completes Acquisition Of ProFibrix For Up To USD 240 Million 39

Medicines Company Completes Acquisition Of Incline Therapeutics For USD 185 Million 41

The Medicines Company, Key Competitors 43

The Medicines Company, Key Employees 44

The Medicines Company, Subsidiaries 45

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

The Medicines Company, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

The Medicines Company (TMC) is a biopharmaceutical company, which provides medical solutions for improving health conditions in patients under critical care. The company's product portfolio comprises marketed products a peptide compound that inhibits an intravenous direct thrombin and needle-free patient-controlled system for short term management of acute postoperative pain for adults requiring opioid analgesia in the hospital. Its pipeline products include an investigational anesthetic agent; and an investigational lipid-lowering drug. TMC also provides acute care generic pharmaceuticals products. The company offers its products for major therapeutic areas, which include surgery and perioperative care, acute care, and cardiovascular care. It has offices and other facilities in the US, the UK, Canada and other European countries. TMC is headquartered in Parsippany, New Jersey, the US.

The Medicines Company (MDCO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

The Medicines Company, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

The Medicines Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

The Medicines Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

The Medicines Company, Medical Devices Deals, 2012 to YTD 2018 10

The Medicines Company, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

The Medicines Company, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Medicines Company Exercises Option to Acquire Recothrom from Bristol-Myers Squibb for USD132 Million 13

Venture Financing 14

Annovation BioPharma Raises USD 8 Million In Series A Financing 14

Annovation BioPharma Raises USD 2 Million In Venture Financing 15

Partnerships 16

The Medicines Company Enters into Agreement with BARDA 16

Medicines Company Enters into Distribution Agreement with Sandoz for Angiomax 17

Licensing Agreements 18

Medicines Company Enters into Licensing Agreement with SciClone 18

Medicines Company Enters Into Licensing Agreement With Bristol-Myers Squibb For Recothrom 20

Medicines Company Enters Into Licensing Agreement With Alnylam Pharma To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 22

Medicines Company Enters Into Licensing Agreement With APP For Acute Care Generic Products 24

Equity Offering 25

The Medicines Company Completes Public Offering Of Shares For USD 201.3 Million 25

Debt Offering 26

The Medicines Company Raises USD402.5 Million in Private Placement of 2.75% Notes Due 2023 26

Medicines Company Raises USD400 million in Private Placement of 2.5% Notes Due 2022 28

The Medicines Company Completes Private Placement Of Notes For USD 275 Million 29

Asset Transactions 30

Melinta Therapeutics Acquires Infectious Disease Business Unit from The Medicines Company 30

Chiesi Farmaceutici Acquires Cardiovascular Assets of The Medicines Company for up to USD743.8 Million 32

Mallinckrodt Acquires Three Topical Hemostasis Drugs from Medicines Company 34

Acquisition 36

Medicines Company Acquires Annovation Biopharma 36

Medicines Company Acquires Rempex Pharma For USD 474 Million 37

Medicines Company Completes Acquisition Of ProFibrix For Up To USD 240 Million 39

Medicines Company Completes Acquisition Of Incline Therapeutics For USD 185 Million 41

The Medicines Company-Key Competitors 43

The Medicines Company-Key Employees 44

The Medicines Company-Locations And Subsidiaries 45

Head Office 45

Other Locations & Subsidiaries 45

Recent Developments 47

Financial Announcements 47

Aug 01, 2018: The Medicines Company Reports Second-Quarter 2018 Results 47

Apr 25, 2018: The Medicines Company Reports First-Quarter 2018 Results 49

Feb 21, 2018: The Medicines Company Reports Fourth-Quarter and Full-Year 2017 Business and Financial Results 51

Oct 25, 2017: The Medicines Company Reports Third-Quarter 2017 Business and Financial Results 53

Aug 09, 2017: The Medicines Company Reports Second Quarter 2017 Business and Financial Results 55

Apr 26, 2017: The Medicines Company Reports First-Quarter 2017 Financial Results 57

Feb 28, 2017: The Medicines Company Reports Fourth-Quarter and Full-Year 2016 Financial Results 58

Corporate Communications 60

Mar 27, 2018: The Medicines Company Announces Chief Financial Officer Transition 60

Feb 27, 2018: The Medicines Company Appoints Dr. Sarah Schlesinger to Its Board of Directors 61

Nov 15, 2017: The Medicines Company Names Dr. Fred Eshelman as Executive Chairman; Appoints Geno Germano to Its Board of Directors 62

Mar 31, 2017: The Medicines Company Appoints Paris Panayiotopoulos to Its Board of Directors 63

Clinical Trials 64

Apr 26, 2017: The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA on Phase III Clinical Program for Inclisiran 64

Mar 17, 2017: The Medicines Company and Alnylam Pharmaceuticals Report Positive Final Results from ORION-1 Phase II Study of Inclisiran 66

Mar 14, 2017: The Medicines Company to Webcast Presentation of ORION-1 Phase II Study of Inclisiran at ACC.17 68

Jan 25, 2017: The Medicines Company to Present Results from ORION-1 Phase 2 Study of Inclisiran at the American College of Cardiology's 66th Annual Scientific Session 69

Jan 08, 2017: The Medicines Company Announces Positive Top-Line Results from Day 180 Interim Analysis in Ongoing ORION-1 Phase 2 Study of Inclisiran 70

Appendix 72

Methodology 72

About GlobalData 72

Contact Us 72

Disclaimer 72


List Of Figure

List of Figures

The Medicines Company, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

The Medicines Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

The Medicines Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

The Medicines Company, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

The Medicines Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

The Medicines Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

The Medicines Company, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

The Medicines Company, Pharmaceuticals & Healthcare, Key Facts, 2017 2

The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

The Medicines Company, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

The Medicines Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

The Medicines Company, Deals By Therapy Area, 2012 to YTD 2018 9

The Medicines Company, Medical Devices Deals, 2012 to YTD 2018 10

The Medicines Company, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Medicines Company Exercises Option to Acquire Recothrom from Bristol-Myers Squibb for USD132 Million 13

Annovation BioPharma Raises USD 8 Million In Series A Financing 14

Annovation BioPharma Raises USD 2 Million In Venture Financing 15

The Medicines Company Enters into Agreement with BARDA 16

Medicines Company Enters into Distribution Agreement with Sandoz for Angiomax 17

Medicines Company Enters into Licensing Agreement with SciClone 18

Medicines Company Enters Into Licensing Agreement With Bristol-Myers Squibb For Recothrom 20

Medicines Company Enters Into Licensing Agreement With Alnylam Pharma To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 22

Medicines Company Enters Into Licensing Agreement With APP For Acute Care Generic Products 24

The Medicines Company Completes Public Offering Of Shares For USD 201.3 Million 25

The Medicines Company Raises USD402.5 Million in Private Placement of 2.75% Notes Due 2023 26

Medicines Company Raises USD400 million in Private Placement of 2.5% Notes Due 2022 28

The Medicines Company Completes Private Placement Of Notes For USD 275 Million 29

Melinta Therapeutics Acquires Infectious Disease Business Unit from The Medicines Company 30

Chiesi Farmaceutici Acquires Cardiovascular Assets of The Medicines Company for up to USD743.8 Million 32

Mallinckrodt Acquires Three Topical Hemostasis Drugs from Medicines Company 34

Medicines Company Acquires Annovation Biopharma 36

Medicines Company Acquires Rempex Pharma For USD 474 Million 37

Medicines Company Completes Acquisition Of ProFibrix For Up To USD 240 Million 39

Medicines Company Completes Acquisition Of Incline Therapeutics For USD 185 Million 41

The Medicines Company, Key Competitors 43

The Medicines Company, Key Employees 44

The Medicines Company, Subsidiaries 45

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

The Medicines Company, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.